trending Market Intelligence /marketintelligence/en/news-insights/trending/FtnXodx0QbM_iIACYHfcZQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Immatics receives $58M funding to develop T-cell therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Immatics receives $58M funding to develop T-cell therapy

immatics biotechnologies GmbH raised $58 million in a series E funding round from existing and new investors.

The company intends to use the funding to develop several T-cell based therapies. The company's main product line includes IMA101, IMA201 and other T-cell receptor candidates. The company will also continue its work on novel tumor targets for cancer immunotherapy, using its XPRESIDENT technology.

The series E funding includes investment from existing investors, Hopp Biotech holding, Wellington Partners, AT Impf GmbH and others. Life sciences company Amgen Inc. also joined the funding round.

Amgen is already partnering with Immatics to develop cancer treatments.